Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells
Authors:
Open Access
- 30 January 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (3) , 1750-1768
Abstract
Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cellsKeywords
This publication has 70 references indexed in Scilit:
- A restricted cell population propagates glioblastoma growth after chemotherapyNature, 2012
- Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal TransitionJournal of Biological Chemistry, 2012
- IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial–Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling PathwayMolecular Cancer Research, 2011
- Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulationsJournal of Hepatology, 2011
- Elevated invasive potential of glioblastoma stem cellsBiochemical and Biophysical Research Communications, 2011
- Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like charactersBMC Cancer, 2011
- Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistanceMolecular Cancer Therapeutics, 2008
- Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene ExpressionCancer Research, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004